We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Antibody responses to the SARS‐CoV‐2 vaccines in hemodialysis patients: Is inactivated vaccine effective?
- Authors
Murt, Ahmet; Altiparmak, Mehmet Rıza; Yadigar, Serap; Yalin, Serkan Feyyaz; Ozbey, Dogukan; Yildiz, Zeynep; Kocazeybek, Bekir; Pekpak, Meltem; Ataman, Muveddet Rezzan
- Abstract
Introduction: Vaccines generally have reduced effectiveness in hemodialysis patients and a similar condition may also apply for the SARS‐CoV‐2 vaccines. The aim of this study was to analyze humoral responses of hemodialysis patients to SARS‐CoV‐2 vaccines. Methods: Eighty‐five maintenance hemodialysis patients who received either inactivated or mRNA SARS‐CoV‐2 vaccines were investigated. Antibody levels were measured by a commercial antibody kit, which detected antibodies toward receptor binding domain of the SARS‐CoV‐2 spike protein. Comparative analyzes were carried between vaccine groups and with a control group of 103 healthy volunteers. Results: Seropositivity rate and antibody levels were significantly lower in hemodialysis patients who received inactivated vaccine (p = 0.000). While mRNA vaccine had better immunogenicity, both vaccines protected from symptomatic infection when seropositivity was achieved. Discussion/Conclusion: When used in the same dose with the general population, inactivated SARS‐CoV‐2 vaccines generate reduced humoral response in hemodialysis patients. mRNA vaccines have better immunogenicity in this group.
- Subjects
COVID-19 vaccines; VACCINE effectiveness; HEMODIALYSIS patients; ANTIBODY formation; HUMORAL immunity
- Publication
Therapeutic Apheresis & Dialysis, 2022, Vol 26, Issue 4, p769
- ISSN
1744-9979
- Publication type
Article
- DOI
10.1111/1744-9987.13752